Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Aurigene Discovery Technologies Ltd
   2. Issuer Name and Ticker or Trading Symbol
CURIS INC [CRIS] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
39-40, KIADB INDUSTRIAL AREA,, PHASE II, ELECTRONIC CITY HOSUR ROAD		 3. Date of Earliest Transaction (Month/Day/Year)
01/18/2015
(Street)

BANGALORE, KARNATAKA, K7 560100		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.01 per share 09/07/2016 09/07/2016 P   10,208,333 A $ 2.4 27,328,464 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Aurigene Discovery Technologies Ltd
39-40, KIADB INDUSTRIAL AREA,
PHASE II, ELECTRONIC CITY HOSUR ROAD
BANGALORE, KARNATAKA, K7 560100		     X    
DR REDDYS LABORATORIES LTD
8-2-337, ROAD NO. 3, BANJARA HILLS
HYDERABAD, TELANGANA, K7 500 034		     X    
Dr. Reddy's Holdings Ltd
7-1-27, AMEERPET
HYDERABAD, TELANGANA, K7 500 016		     X    

Signatures

 AURIGENE DISCOVERY TECHNOLOGIES LIMITED, By: /s/ Ashish Lath, Name: Ashish Lath, Title: Director of Finance   09/08/2016
**Signature of Reporting Person Date
 DR. REDDY'S LABORATORIES LIMITED, By: /s/ Saumen Chakraborty, Name: Saumen Chakraborty, Title: President and Chief Financial Officer   09/08/2016
**Signature of Reporting Person Date
 DR. REDDY'S HOLDINGS LIMITED, By:/s/ G V Prasad, Name: G V Prasad, Title: Director   09/08/2016
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 
Remarks:
Aurigene Discovery Technologies Limited ("Aurigene") has acquired from the Issuer an additional 10,208,333 shares of Common Stock, par value $0.01 per share, of the Issuer at a purchase price of $2.40 per share.

1. This Form 4 is being filed jointly by (i) Aurigene Discovery Technologies Limited ("Aurigene"), which (after giving effect to the acquisition of an additional 10,208,333 shares as described above) directly holds 27,328,464 shares of Common Stock of the Issuer (the "Reported Securities"), (ii) Dr. Reddy's Laboratories Ltd. ("DRL"), as the parent company and 100% owner of Aurigene, and (iii) Dr. Reddy's Holdings Ltd. ("DRHL"), in the event that it could be deemed to "beneficially own" the Reported Securities as the result of its ownership of voting securities of DRL.

2. In the event that DRHL could be deemed to "beneficially own" the Reported Securities as the result of its ownership of voting securities of DRL, its proportional pecuniary interest in such Reported Securities would be approximately 24.262%, which would represent approximately 6,630,545 shares of Common Stock of the Issuer.

3. The filing of this Form 4 shall not be deemed an admission for the purposes of Section 16 or any other purpose that any reporting person is the beneficial owner of any Reported Securities, and DRHL expressly disclaims that it is the beneficial owner of any of the Reported Securities.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.